1

2 **Reproducible Community Dynamics of the Gastrointestinal Microbiota**

3 **Following Antibiotic Perturbation**

4

5

6 Dionysios A. Antonopoulos[1], Susan M. Huse[3], Hilary G. Morrison[3], Thomas M.

7 Schmidt[4], Mitchell L. Sogin[3], Vincent B. Young[1,2*]

8

9 [1]Department of Internal Medicine/Division of Infectious Diseases, [2]Department of

10 Microbiology & Immunology, The University of Michigan, Ann Arbor, MI, 48109,

11 USA; [3]The Marine Biological Laboratory, Woods Hole, MA, 02543, USA;

12 [4]Department of Microbiology and Molecular Genetics, Michigan State University,

13 East Lansing, MI, 48824, USA

14

15 Running Title: Antibiotics and Gut Microbiota

16

17 *Corresponding author:

18

19 **Vincent B. Young, MD/PhD**

20 The University of Michigan

21 4618D Med Sci II SPC 5623

22 1150 W. Medical Center Dr.

23 Ann Arbor, MI 48109-5623

24 Office: 734-764-2237

25 Lab: 734-763-4133

26 Fax: 734-763-4168

27 Email: youngvi@umich.edu

28

29 Abbreviations

30 V6, sixth hypervariable region of the 16S ribosomal RNA-encoding gene; AMB,
31 amoxicillin, metronidazole and bismuth; SSU, small subunit; rRNA, ribosomal
32 RNA; GAST, global alignment for sequence taxonomy; RDP, ribosomal database
33 project; OTU, operational taxonomic unit; GI, gastrointestinal; SPF, specific
34 pathogen free

Abstract

Shifts in microbial communities are implicated in the pathogenesis of a number of gastrointestinal diseases, but we have limited understanding of the mechanisms that lead to altered community structures. One difficulty with studying these mechanisms in human subjects is the inherent baseline variability of the microbiota in different individuals that arise due to varying life histories. To try and overcome this baseline variability we employed a mouse model to control host genotype, diet and other possible influences on the microbiota. This allowed us to determine if the indigenous microbiota in such mice had a stable baseline community structure and whether this community exhibited a consistent response following antibiotic administration. We employed a tag sequencing strategy targeting the V6 hypervariable region of the bacterial small-subunit (16S) ribosomal RNA combined with massively parallel sequencing to determine the community structure of the gut microbiota. Inbred mice in a controlled environment harbored a reproducible baseline community that was significantly impacted by antibiotic administration. The ability of the gut microbial community to recover to baseline following cessation of antibiotic administration varied according to the antibiotic regimen administered. Severe antibiotic pressure resulted in reproducible long-lasting alterations in the gut microbial community including a decrease in overall diversity. The finding of stereotypic responses of the indigenous microbiota to ecologic stress implies that a better understanding of the factors that govern community structure could lead to strategies for the

57 intentional manipulation of this ecosystem to preserve or restore a healthy

58 microbiota.

Introduction

A highly diverse, complex community of microorganisms inhabits the gastrointestinal tract of mammals. This community, referred to as the indigenous microbiota, exists in a delicate symbiosis with the host (3, 15). A significant body of research has demonstrated that disturbances in this balance can disrupt intestinal homeostasis. Multiple disease states may arise, at least in part, in response to altered indigenous microbial communities in the gut (10, 47, 53, 56). Conversely, research on probiotics indicates the normal balance between the indigenous microbiota and the host can be protected or restored through administration of beneficial microbes (6, 45, 60).

The relationship between the indigenous microbiota and a host involves multiple interactions. The indigenous microbiota play a central role in digestion and nutrition of the host (30, 56). These microbes also affect the regulation and homeostasis of the host immune system (27, 46). As part of the innate defenses of the gastrointestinal tract, the community of indigenous microbes forms and ecologic barrier that prevents the ingress of pathogenic microorganisms. For example, the development of *Clostridium difficile*-associated colitis following antibiotic administration arises from a loss of intrinsic “colonization resistance” against pathogenic organisms (61). Antibiotic disturbance of the normal community structure of the microbiota may allow germination of environmentally acquired spores with subsequent overgrowth of the pathogen and toxin production. Alternatively, *C. difficile* colitis may develop subsequent to the expansion of low-abundance *C. difficile* populations that normally produce

82 insignificant levels of toxin. In either case, the disruption of the indigenous
83 microbiota by antibiotic administration is a key component of pathogenesis (7).
84 Murine models have provided important insights about the interactions
85 between the microbiota and the host. One consistent feature of microbiota
86 studies in human subjects is that there is significant interindividual variation in the
87 indigenous microbiota (12, 13). This variation likely arises from the accumulated
88 effects of genetic and environmental influences on the gut microbial community
89 (11). Significant baseline variation makes it difficult to conduct studies that follow
90 the dynamics of the gut microbiota in humans, especially if the goal is to discern
91 stereotypic responses to a given manipulation. Therefore, as with other areas of
92 biomedical research, murine models offer unique advantages for microbiota
93 experimentation.
94 Several recent studies describe murine models of disease in which altered
95 indigenous gut microbial communities are generated through the administration
96 of antibiotics. These altered communities can either be permissive or required for
97 the development of the model disease state, although in other cases they appear
98 to be protective (5, 9, 24, 26, 52). Although these studies have provided insight
99 into many of the host responses to the indigenous microbiota, we have
100 remarkably little information as to the exact nature of the effect of antibiotic
101 administration on the microbial communities themselves. For example, these
102 studies assume that genetically identical mice would harbor a consistent baseline
103 microbiota. Furthermore, it is also assumed that the microbiota respond in a
104 reproducible manner to the antibiotic administration resulting in consistent

105 changes in the structure and function of the microbiota responsible for the
106 observed changes in the host response. These crucial assumptions have not
107 been rigorously tested to date.

108 Early studies on the gut microbiota relied upon culture-based techniques
109 that characterizes only a small fraction of the microbial diversity present (19). The
110 introduction of molecular techniques e.g. DNA sequencing of PCR amplicons
111 from ribosomal RNA genes, allowed the detection and enumeration of
112 microorganisms that are refractory to cultivation (41, 62). Each sequence serves
113 as a proxy for the occurrence of a microbial genome in a microbial community.
114 Most of the amplicon sequences from the human gut microbiota correspond to
115 Firmicutes or Bacteroidetes (13) and their total complexity exceeds 15,000
116 different operational taxonomic units (OTUs) (42).

117 For most complex microbial communities including the gut microbiota, a
118 small number of phylotypes dominate population structures and mask the
119 appearance of many distinct but low-abundance taxa in most molecular surveys
120 (55). A meaningful comparison of microbial population structures for different
121 complex communities requires analysis of many thousands of PCR amplicon
122 sequences in order to estimate the relative abundance of different phylotypes
123 and to detect the presence of rare taxa. Recent advances in DNA sequencing
124 technology have permitted the development of methods for deep culture-
125 independent surveys of microbial diversity at relatively low cost. In this
126 communication we conducted controlled experiments to characterize the
127 changes in the community structure of the murine gastrointestinal microbiota

128 during antibiotic administration and to monitor the response of this community
129 after withdrawal of drug. Using a high-throughput 16S tag sequencing approach
130 targeting the V6 hypervariable region (21, 55), we gained an unprecedented view
131 of the diversity present in the gut microbiota and were able to detail the dynamics
132 of the gut microbial community during periods of ecologic stress brought on by
133 antibiotic administration. We find that antibiotic administration results in
134 reproducible, significant, and in some cases, long lasting, changes in the
135 community structure of the gut microbiota. These changes most likely disturb the
136 balanced interactions between the indigenous microbiota and the host and
137 account for observed changes in gut homeostasis that have been shown to result
138 from antibiotic administration in both clinical and experimental settings.

139 Materials and Methods

140 **Mouse models and housing conditions.** C57BL/6 IL-$10^{-/-}$ mice were from a
141 breeding colony maintained in specific pathogen free conditions at Michigan
142 State University (MSU), derived from mice originally purchased from Jackson
143 Laboratories (Bar Harbor, ME). C57BL/6J wild-type mice were purchased directly
144 from Jackson Laboratories and housed with autoclaved food, bedding, and
145 water. For the antibiotic therapy experiments selected four- to six-week old mice
146 were either treated with antibiotics supplemented in their food (amoxicillin [3.0
147 mg], metronidazole [0.69 mg] and bismuth [0.185 mg] formulated per 5 gram
148 tablet/day/average [20 g] mouse [BioServ, Frenchtown, NJ]) or in their drinking
149 water (cefoperazone [0.5 mg/mL] [Sigma-Aldrich]). Experiments with amoxicillin,
150 metronidazole and bismuth were carried out at the University Research

151 Containment Facility at MSU and the experiments with cefoperazone were
152 carried out in the Unit for Laboratory Animal Medicine at the University of
153 Michigan. All experimental protocols were approved the animal use and care
154 committees at the respective institutions.
155 **Sample collection and DNA extraction.** At the conclusion of the experiments,
156 mice were euthanized by CO_2 asphyxiation. The cecum of each mouse was
157 removed and washed in phosphate-buffered saline to remove luminal contents.
158 The cecal tip was then excised, bisected, and snap-frozen in liquid nitrogen prior
159 to storage at -80º C. Genomic DNA was then extracted from cecal tip samples
160 (25-100 mg) with the QIAGEN DNeasy® Blood & Tissue Kit using a modified
161 protocol. These modifications included: (1) adding a bead beating step using
162 UltraClean™ Fecal DNA Bead Tubes (MO BIO Laboratories, Inc.) that were
163 shaken using a MiniBeadbeater-8™ (BioSpec Products, Inc.) at the
164 "homogenize" setting for one minute; (2) increasing the amount of Buffer ATL
165 used in the initial steps of the protocol (from 180 μL to 360 μL); (3) increasing the
166 volume of proteinase K used (from 20 μL to 40 μL); and (4) decreasing the
167 amount of Buffer AE used to elute the DNA at the end of the protocol (decreased
168 from 200 μL to 100 μL).
169 **Sequencing and data analysis.** The data presented here are based on 39 PCR
170 amplicon libraries sequenced in five 454 runs using the GS-FLX platform (454
171 Life Sciences, Roche Diagnostics Corp). V6 tag sequence amplicon libraries
172 were constructed as previously described (54). Primer sets corresponding to
173 967F and 1046R used in the library preparation and the permuted primer

174 approach for sequencing multiple libraries within a single GS-FLX 454 run
175 without use of a physical partition are described in Huber et al., 2007 (21).
176 Primers were trimmed off and all sequences without an exact match to the
177 forward primer, shorter than 50 nt, or containing ambiguous base calls were
178 removed as low quality reads. Sequences were organized in a relational
179 database, and operational taxonomic units were created by aligning with
180 MUSCLE and clustering with DOTUR as described in Huber et al., 2007 (14, 21,
181 50). Taxonomic assignments were made through direct comparison of tags to a
182 reference database of close to 200,000 distinct V6 sequences and using a
183 consensus of the nearest tags in a global alignment of tags and reference
184 sequences (22).
185 **Quantitative PCR.** Quantitative PCR reactions were used to separately assay
186 the quantity of rRNA operons in the DNA samples relative to a singe-copy host
187 gene (mouse TNF-α). A portion of the 16S rRNA encoding gene from
188 *Helicobacter hepaticus* 3B1 was cloned and used as a positive control (between
189 positions 331 and 797 based on *Escherichia coli* numbering of the 16S rRNA
190 gene). A 264-bp portion of the gene encoding TNF- α from *Mus musculus* was
191 also cloned and used as a positive control for the host gene target (between
192 positions 6455 and 6718 of the mouse TNF- α encoding gene; GenBank
193 accession number Y00467). Plasmids were purified from each clone and a 10-
194 fold dilution series was used to determine detection limits of the assay as well as
195 provide standard curves for absolute quantification in the qPCR reactions (range
196 of 10^1-10^7 copies per reaction). Assay volumes were comprised of the

197 LightCycler® 480 Probes Master reaction mix (Roche) at 1x concentration, and
198 appropriate primer-probe sets to increase specificity of the detected signals from
199 the sample DNA (100 ng). For detection of the bacterial signal 100 nanomoles of
200 each of the forward and reverse primers and the fluorogenic probe were included
201 in the reactions. Sequences for the forward primer (5'-
202 TCCTACGGGAGGCAGCAGT-3'), the reverse primer (5'-
203 GGACTACCAGGGTATCTAATCCTGTT-3'), and the probe (5'-[6-FAM]-
204 CGTATTACCGCGGCTGCTGGCAC-[TAMRA]-3') were based on Nadkarni et al.,
205 2002 (39). Final assay volumes of 20 μL were dispensed in triplicate in 96-well
206 plates. Signals were detected with a LightCycler 480 instrument (Roche). The
207 reaction conditions for amplification of DNA were 95 °C for 10 minutes and 40
208 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Detection of the host
209 signal used 200 nanomoles of the forward (TNFa_mu_se; 5'-
210 GGCTTTCCGAATTCACTGGAG-3') and reverse primers (TNFa_mu_as; 5'-
211 CCCCGGCCTTCCAAATAAA-3'), and 100 nanomoles of the probe
212 (TNFa_mu_probe; 5'-[Cy5]-ATGTCCATTCCTGAGTTCTGCAAAGGGA-[Iowa
213 Black RQ™]-3') adapted from Nitsch et al., 2001 (40). Amplification of the host
214 signal began with an incubation at 95°C for 10 minutes, followed by 45 cycles of
215 95°C for 20 seconds and 64°C for 30 seconds. Comparison in relative bacterial
216 load was performed via the $\Delta\Delta C_T$ method normalizing the 16S signal to the host
217 signal (51).

218 # Results

219 **Antibiotic administration alters the structure of the gut microbiota**

220 To characterize the impact of antibiotic administration on the composition
221 of the gut microbiota, a combination of amoxicillin, metronidazole and bismuth
222 (AMB) was administered to C57BL/6 IL-10$^{-/-}$ mice via their chow for 10 days
223 (Figure 1). The C57BL/6 IL-10$^{-/-}$ strain was chosen as it is utilized as model of
224 inflammatory bowel disease that is responsive to antibiotic therapy (33). The
225 microbial community in one group of mice was assessed immediately following
226 the 10-day treatment, while a second group of mice was switched back to drug
227 free chow for two weeks before microbial community analysis. The microbiota
228 from mice in both groups were compared to a group of control mice that had
229 been fed conventional chow for the duration of the study.

230 We used a massively-parallel pyrosequencing strategy to retrieve
231 sequences of the V6 hypervariable region of the small-subunit (SSU) rRNA gene
232 (55) to determine the composition of the microbial community associated with the
233 cecal mucosal of these was mice. These SSU sequence tags are generated by
234 PCR amplification and function as proxies for the presence of individual
235 phylotypes present in a given community. The use of pyrosequencing permitted
236 characterization of a greater number of phylotypes than previously practical via
237 PCR amplification, cloning and capillary sequencing of SSU genes. GAST
238 (Global Alignment for Sequence Taxonomy) provided taxonomic assignments for
239 each of the tag sequences (22).

240 We collected a total of 1,006,137 sequence tags were generated from
241 representative samples (9 control, 2 treated and 10 treated followed by
242 recovery). The vast majority of the sequence tags recovered from the cecal
243 community of control animals affiliated with the phyla Bacteroidetes and
244 Firmicutes, with only about 1% belonging to Proteobacteria (Figure 2, Table S1).
245 In the antibiotic-treated animals however, the majority of tags (73,010 of 102,822,
246 [71%]) were Proteobacteria. Two specific tags, assigned to the family
247 Enterobacteriaceae accounted for 67,717 (93%) of these Proteobacteria tags
248 (Table S2). In the control animals, these two tags represented only 106 out of a
249 total of 5214 (2%) tags belonging to Proteobacteria.
250 In the animals whose gut microbial community was allowed to recover via
251 a two-week antibiotic-free period, Firmicutes and Bacteroidetes returned to
252 dominance (70% and 22% of the total number of tags, respectively).
253 Proteobacteria decreased to 5.77% of the total, greater than the 1.2% in the
254 animals that never received antibiotics, but much less than the 73% that they
255 comprised at the end of the AMB treatment (Figure 2). The relative increase in
256 Proteobacteria resulted from increases in tags that mapped to several taxonomic
257 groups within the phylum (Table S1). The two Enterobacteriaceae tags that were
258 dominant in the AMB-treated mice were encountered only 201 times out of a total
259 of 26,964 (0.75%) Proteobacteria tags (Table S2).
260 A global comparison of all of the gut microbial communities in each of the
261 animals was performed by calculating the Bray-Curtis measure of community
262 similarity (34). This index is based upon presence/absence and relative

263 abundance of each phylotype encountered the mucosa-associated communities.
264 We calculated the average Bray-Curtis similarity for each pair-wise comparison
265 of the control, treated and recovered animals (Table 1). ANOVA of these Bray-
266 Curtis values confirmed that the mucosa-associated microbiota from antibiotic
267 treated animals differed significantly from both the control animals and the
268 recovered animals ($p < 0.05$). The average Bray-Curtis similarity comparing
269 communities from antibiotic-treated animals to communities from the other two
270 experimental groups was significantly lower.

271 **Variability in the murine gut microbiota**

272 Despite the significant differences in the gut microbiota between control
273 animals and animals that received the triple antibiotic cocktail, there was still
274 inter-animal variation noted within each experimental group. The animals in this
275 experiment were selected from a breeding colony maintained at Michigan State
276 University over a time period of approximately 5 months. The animals therefore
277 came from several different litters born to separate mothers.

278 To determine the degree of similarity amongst animals that shared as
279 many variables as possible, we sequenced and compared 48,594 V6 sequence
280 tags from the mucosa-associated microbiota located in the cecae of three age-
281 matched, wild-type C57BL/6 mice purchased from a commercial vendor. Figure 3
282 depicts the results of taxonomic assignments and Bray-Curtis measures of
283 community similarity based upon presence/absence and relative phylotype
284 abundance from the mucosa-associated community of each animal. As observed
285 previously, Firmicutes and Bacteroidetes dominated the microbial communities in

286 the cecae of each of the three animals. All three communities displayed similar
287 phylotype distributions at all taxonomic levels with Bray-Curtis similarities > 0.9
288 for all pairwise community comparisons. We recovered approximately 16,000
289 tags from each community (Figure 3). Using an operational taxonomic unit (OTU)
290 assignment of 97% sequence similarity, this yielded ~1000 OTUs in each
291 community. The non-parametric Chao1 estimator (8), suggests that for this
292 sampling effort, there are ~1200 unique 97% OTUs in each mucosa-associated
293 gut community.

294 Antibiotic administration can result in a prolonged decrease in the 295 diversity of the gut microbiota

296 In spite of the dramatic shifts in the composition of the gut microbiota
297 following administration of the amoxicillin, metronidazole and bismuth cocktail,
298 the community structure returned largely to the baseline state two weeks after
299 discontinuation of the drugs. In an additional pilot experiment, the broad-
300 spectrum cephalosporin antibiotic cefoperazone appeared to have a similar
301 dramatic effect on the microbiota of C57BL/6 IL-10$^{-/-}$ mice, but in this case there
302 were significant long-term effects on the community structure, including lower
303 overall diversity, after antibiotic recovery (data not shown).

304 To extend this initial observation, we undertook an additional antibiotic
305 administration trial employing cefoperazone in twenty female wild type C57BL/6
306 mice (Figure 1B). Five mice were maintained in a single cage on standard mouse
307 chow and sterile water (control group). The remaining 15 mice were switched to
308 water supplemented with cefoperazone (0.5 mg/mL) and after 10 days, these

309 antibiotic-treated mice were divided into three subsequent treatments. Three
310 mice were immediately euthanized to observe the effects of cefoperazone on the
311 gut microbiota. Six mice, housed three animals per cage, were returned to sterile
312 water for six weeks (isolated recovery) while another group of six mice (again
313 divided into two cages) were housed with a control mouse added to each cage
314 during the antibiotic-free period (donor recovery). The addition of the control
315 mouse allowed reinoculation of the gut microbiota via natural coprophagic
316 activity.

317 We recovered a total of 308,505 tag sequences were recovered from the
318 seventeen samples representing the animals in the three experimental groups
319 (Table S3). On average ~18,000 high quality sequence tags (23) were recovered
320 per sample. Amplification of sequence tags was not possible for the three
321 cefoperazone-treated mice that were euthanized at the end of antibiotic
322 treatment (without a drug-free recovery period). Real-time PCR targeting the 16S
323 SSU gene was used to determine to what effect the antibiotics had on overall
324 bacterial load (judged by the relative ratio of the 16S SSU signal to a genomic
325 murine target gene), and whether this could explain the inability to amplify
326 sequence tags from these animals. The bacterial load in animals treated with
327 antibiotics decreased by three orders of magnitude (average fold change 4300)
328 compared to control animals. Both groups of animals that were allowed to
329 recover from antibiotic administration for 6 weeks (isolated recovery and donor
330 recovery) had levels of bacteria that were comparable to the control animals

331 (average fold change 0.91 for donor recovery animals and 1.20 for isolated
332 recovery animals).
333 Pairwise Bray-Curtis similarities are displayed in heatmap format (Figure
334 4) to allow visualization of all of the pair-wise comparisons. The bacterial
335 community in cefoperazone-treated animals six weeks after discontinuation of
336 the drug was distinct from that in control animals. However, the microbial
337 community in the animals that recovered from antibiotic-administration in the
338 presence of an untreated donor animal returned to a state that was very similar
339 to that seen in the control animals.
340 When we examined the composition of the phylotypes at the level of
341 phylum, the primary distinction was a reduction of Bacteroidetes diversity in the
342 animals that recovered without additional input of microbes. While phylotypes
343 assigned to Bacteroidetes comprised about 15% of the total community in the
344 control animals and in the animals that recovered in the presence of a donor
345 animals, they were only 0.33% of the total community in the animals that
346 recovered in the absence of a donor.
347 At finer levels of taxonomic distinction, there were additional differences
348 noted between the animals that did not have a donor animal present during the
349 recovery phase compared to either the control animals or those that recovered
350 with a donor (Figure 5 Table S3). At the genus level, the composition of the
351 microbial community from controls and recovery with donor animals was quite
352 different from the composition of the community from animals that recovered

353 without a donor. These data also suggest that the gut community in animals that
354 recovered without a donor was composed of a decreased number of phylotypes.
355 Rarefaction curves demonstrated there were fewer phylotypes present in
356 the microbial community from animals that recovered without a donor.
357 Rarefaction analysis involves resampling of community survey data to generate
358 idealized collector's curves, providing an indication of overall phylotype richness
359 (17, 34). In addition, rarefaction can provide an estimate of the depth to which a
360 complex community has been sampled. Rarefaction curves from the control
361 animals and the animals that recovered in the presence of a donor overlapped,
362 confirming that the overall diversity (phylotype richness) was similar between the
363 two (Figure 6). Conversely, rarefaction analysis of the communities from the
364 animals that recovered without a donor indicated that the diversity of these
365 communities was lower than for the other two experimental groups.

366 Discussion

367 The myriad interactions between the indigenous gastrointestinal
368 microbiota and their mammalian host have been a focus of considerable recent
369 scientific investigation. Studies on human subjects have the advantage of
370 directly examining the natural community responsible for specific diseases.
371 However, due to technical and ethical constraints of examining the human
372 microbiota, a great deal of effort has been applied to studying model systems, in
373 particular murine models.
374 Two main lines of research have provided insights about host/microbiota
375 interactions in murine models. Studies in germ free and gnotobiotic mice have

376 demonstrated that gut bacteria can transmit signals that influence host responses
377 (20, 44). However, these are highly simplified systems where community
378 complexity is orders of magnitude lower than naturally occurring murine
379 microbiota. An alternative approach has been to study ecologic stressors shape
380 complex communities in murine model systems. In many cases antibiotics are
381 employed to alter the indigenous microbiota thus disturbing the normal, baseline
382 host/microbe interactions. Such an approach has demonstrated a role for the
383 microbiota in genetic models of murine inflammatory bowel disease (26, 33) and
384 in the modulation of glucose tolerance in mouse models of insulin resistance
385 (37). Antibiotic treatment studies have shown that antibiotic resistant bacterial
386 pathogens can exploit innate immune deficits triggered by antibiotic
387 administration (5). Antibiotic regimens have been used to demonstrate a role for
388 the indigenous microbiota in shaping physiologic responses of the gut mucosa
389 including mediating protective responses to direct epithelial injury (43) and
390 directing the differentiation of IL-17-producing T-helper cells in the mucosa of the
391 small intestine (24). Antibiotic treated mice demonstrate altered susceptibility to
392 experimental infection with pathogenic bacteria. Streptomycin treatment of mice
393 increases susceptibility to oral infection with *Salmonella enterica* serovar
394 Typhimurium (52). A recently described murine model of *Clostridium difficile*-
395 associated colitis employed pretreatment with a mixture of five antibiotics
396 followed by a single dose of clindamycin a day prior to oral challenge with *C.*
397 *difficile* (9).

398 The focus of these studies has generally been on the host response to the
399 alteration in the indigenous microbiota. In most cases the nature of the antibiotic-
400 induced changes on the microbiota were not investigated. Some studies
401 measured changes in total aerobic and anaerobic colts available bacteria
402 following antibiotic administration and in a few cases limited culture-independent
403 investigation of the microbiota was performed. An implicit assumption for these
404 studies is that genetically identical mice harbor a consistent baseline microbiota.
405 A further assumption is that the use of antibiotics would result in reproducible
406 changes in the microbiota that were responsible for the altered host responses
407 observed. This critical assumption has never been formally addressed in detail
408 until the current study.
409 It has been proposed that an adult mammal harbors a stable, "climax
410 community" in each anatomic area of the GI tract (48). Although there can be
411 individual variation in the composition of shallow phylogenetic lineages within the
412 gut microbiota, there are relatively few deep lineages, with Firmicutes and
413 Bacteroidetes generally dominant in most surveys (11, 29). These observations
414 most likely reflect the influence of a variety of ecologic and evolutionary
415 constraints on the gut microbial community (28, 29). Our results, demonstrating
416 marked similarity between the gut microbiota from individual animals, albeit
417 among individuals with identical genetic background maintained in a tightly
418 controlled environment, provide strong evidence that the gut microbial community
419 represents a stable ecosystem. This high degree of similarity also provides

420 evidence for the existence of community “assembly rules” that govern the
421 establishment and stability of these microbial consortia.
422 Perhaps the more critical assumption in experiments that involve antibiotic
423 manipulation of the indigenous gut microbiota is that drug treatment results in
424 reproducible alterations of the microbial community structure. The relative
425 stability of the indigenous microbiota has been debated. From an ecological
426 standpoint, the term stability (also commonly referred to as robustness)
427 encompasses a number of components (2, 31). One aspect is temporal stability,
428 which is the constancy of community structure over time. In addition, the term
429 resistance refers to the ability of a community to maintain a given structure in the
430 setting of a perturbation, while resilience is the ability of a community to return to
431 its baseline structure following a perturbation in community structure. In this
432 regard, if a community exhibits temporal stability, this implies the presence of
433 resistance and resilience in the community structure as one assumes that most
434 communities will experience ecologic stress at some point in time.
435 A number of studies have indicated that an individual’s gut microbiota can
436 have a relatively stable community composition over a period of months to years
437 (36, 49, 58, 63). These observations have led to the conclusion that the
438 community of microbes in the gut is relatively resistant to perturbation by various
439 ecologic stressors. Subsequent environmental influences including diet, host
440 genetics, medication use, and exposure to infectious agents can all have an
441 influence on the resultant microbial community (11). It has been reported that
442 short-term administration of antibiotics (a 7 day course of clindamycin) could

443 result in long-term changes in the structure of the fecal microbiota of humans (12,
444 25, 32). In all of these human studies, there was considerable individual baseline
445 variation in the microbiota, which made it difficult to make inter-individual
446 comparisons in the microbiota responses.

447 Although human studies such as these are important, one advantage of
448 conducting murine experiments as described herein is that the ability to conduct
449 true controlled, replicate experiments. Our replicate experiments allowed us to
450 detect consistent shifts in the gut microbial community in the response to
451 antibiotic administration. The reproducibility of these changes indicates that even
452 if the influences on microbial community structure are complex and numerous,
453 the community will exhibit stereotypic responses, if ecologic stressors are
454 consistently applied. We observed reproducible shifts in the community structure
455 of the gut microbiota following antibiotics including significant alterations in both
456 the richness and distribution of 16S V6 phylotypes. The power of a deep survey
457 of diversity allowed us to demonstrate that certain low abundance phylotypes
458 present at baseline could become dominant in response to the shift in
459 environmental conditions brought about by antibiotic administration. In control
460 animals, 16S V6 tag sequences corresponding to members of the family
461 Enterobacteriaceae comprised only a small fraction of the populations (1%).
462 During administration of amoxicillin, metronidazole and bismuth (AMB), this
463 group of organisms became the most dominant phylotype, indicating that this
464 antibiotic regimen created an environment that somehow favored this taxonomic
465 group of organisms. Simple resistance to the antibiotics cannot entirely explain

466 this observation as other phylotypes were unchanged in relative abundance
467 following AMB administration, but did not undergo the remarkable relative
468 expansion during drug treatment exhibited by the Enterobacteriaceae.

469 In this case, the gut microbial community exhibited resilience as the
470 community structure shifted back towards the baseline state following cessation
471 of the AMB treatment. However, the ability of this community to recover following
472 antibiotic disturbance was not absolute. The administration of cefoperazone also
473 caused dramatic shifts in community structure, but in this case, diversity did not
474 recover even six weeks after the discontinuation of the drug. Rarefaction analysis
475 revealed a persistent, significant decrease in overall species richness in the gut
476 community following cefoperazone administration. However, the addition of an
477 untreated mouse to cages of cefoperazone-treated animals during the recovery
478 phase allowed complete restoration of diversity, presumably through natural
479 coprophagic activity. This observation indicates that cefoperazone administration
480 did not change host physiology, as exposure to a baseline microbiota resulted in
481 normalization of the community structure. Additionally, we infer that the baseline
482 community structure is “preferred” since all four animals in the cage possessed a
483 community that we not distinguish from that in untreated control animals. Since
484 the donor animal were exposed to the altered community present in the
485 cefoperazone-treated animals, it is possible that the resultant communities would
486 possess the antibiotic-altered community structure or an intermediate structure.

487 The reasons for the observed differences in community resilience are not
488 entirely clear. The ecologic disturbance mediated by cefoperazone appears to

489 have overcome the community resilience, potentially due to different spectra of
490 anti-microbial activity. Regardless of the underlying reasons for the differences
491 in observed community resilience, from an experimental standpoint it is important
492 to understand that manipulation of the indigenous gut microbiota by various
493 antibiotic regimens may result in altered community structures that persist even
494 after the antibiotic is discontinued. Whether or not the gut community returns to
495 the baseline state after perturbation can influence the conclusions that can be
496 drawn from a particular experiment.

497 The implications of long-lasting changes in community diversity following
498 antibiotic administration are several-fold. Even though the microbial composition
499 of the animals that recovered from cefoperazone treatment remained altered
500 compared to baseline, overall bacterial biomass returned to the level observed in
501 control mice. It has been postulated that functional redundancy in complex
502 microbial communities can allow an altered community to perform equivalent
503 ecosystem functions as the original community (2). Studies are ongoing to
504 determine if the specific alterations in the gut microbiota result in any significant
505 changes in gut ecosystem functioning.

506 One function of the gut microbiota that has captured our attention is that of
507 "colonization resistance", the ability of the indigenous microbiota to prevent
508 ingress of pathogens into the gut community (16, 18, 59). Antibiotic associated
509 colitis resulting from *Clostridium difficile* infection may result from a loss of the
510 intrinsic colonization resistance of the gut microbiota (4, 38). Theoretically, the
511 administration of antibiotics could disturb the indigenous microbiota allowing *C.*

512 *difficile* spores encountered in the environment to germinate and successfully
513 colonize the gut (4, 61). Although *C. difficile* infection responds to the
514 administration of specific anti-microbial therapy, including metronidazole or
515 vancomycin, recurrence following the end of *C. difficile* therapy has become an
516 increasing problem (35). In a previous study, we have provided evidence that
517 recurrent *C. difficile* infection is associated with a decrease in fecal microbial
518 diversity (7). This observation is in line with the fact that the administration of
519 stool from healthy individuals to patients with recurrent *C. difficile* can break the
520 cycle of recurrence (1, 57). The data presented here indicate that antibiotic
521 therapy of sufficient magnitude can result in an altered microbial community. It
522 remains to be determined if this can be directly correlated with a loss of
523 colonization resistance, but our findings provide evidence that antibiotic
524 administration can result in long term decreases in gut microbial diversity, which
525 in turn is associated with recurrent *C. difficile* disease.

526 As we learn more about the intricate relationship between the gut
527 microbiota and their host we may find that unintended disturbance of this
528 microbial community will have significant deleterious health effects. A more
529 complete understanding of the ecologic forces that determine the formation and
530 maintenance of microbial community structures could lead to novel ways to
531 prevent or treat diseases that result from disruptions of the gut microbiota.

532 # References

533

534 1. **Aas, J., C. E. Gessert, and J. S. Bakken.** 2003. Recurrent *Clostridium*
535 *difficile* colitis: case series involving 18 patients treated with donor stool
536 administered via a nasogastric tube. Clin Infect Dis **36:**580-5.
537 2. **Allison, S. D., and J. B. Martiny.** 2008. Colloquium paper: resistance,
538 resilience, and redundancy in microbial communities. Proc Natl Acad Sci
539 U S A **105 Suppl 1:**11512-9.
540 3. **Backhed, F., R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I.**
541 **Gordon.** 2005. Host-bacterial mutualism in the human intestine. Science
542 **307:**1915-20.
543 4. **Bartlett, J. G.** 2008. Historical perspectives on studies of *Clostridium*
544 *difficile* and *C. difficile* infection. Clin Infect Dis **46 Suppl 1:**S4-11.
545 5. **Brandl, K., G. Plitas, C. N. Mihu, C. Ubeda, T. Jia, M. Fleisher, B.**
546 **Schnabl, R. P. DeMatteo, and E. G. Pamer.** 2008. Vancomycin-resistant
547 enterococci exploit antibiotic-induced innate immune deficits. Nature
548 **455:**804-7.
549 6. **Broekaert, I. J., and W. A. Walker.** 2006. Probiotics and chronic disease.
550 J Clin Gastroenterol **40:**270-4.
551 7. **Chang, J. Y., D. A. Antonopoulos, A. Kalra, A. Tonelli, W. T. Khalife,**
552 **T. M. Schmidt, and V. B. Young.** 2008. Decreased Diversity of the Fecal
553 Microbiome in Recurrent *Clostridium difficile*-Associated Diarrhea. J Infect
554 Dis **197:**435-8.
555 8. **Chao, A.** 1984. Non-parametric estimation of the number of classes in a
556 population. Scand J Stat **11:**265-270.
557 9. **Chen, X., K. Katchar, J. D. Goldsmith, N. Nanthakumar, A. Cheknis, D.**
558 **N. Gerding, and C. P. Kelly.** 2008. A Mouse Model of *Clostridium difficile*-
559 Associated Disease. Gastroenterology **In press (Epub ahead of press)**.
560 10. **De La Cochetiere, M. F., T. Durand, V. Lalande, J. C. Petit, G. Potel,**
561 **and L. Beaugerie.** 2008. Effect of antibiotic therapy on human fecal
562 microbiota and the relation to the development of *Clostridium difficile*.
563 Microb Ecol **56:**395-402.
564 11. **Dethlefsen, L., P. B. Eckburg, E. M. Bik, and D. A. Relman.** 2006.
565 Assembly of the human intestinal microbiota. Trends Ecol Evol.
566 12. **Dethlefsen, L., S. Huse, M. L. Sogin, and D. A. Relman.** 2008. The
567 pervasive effects of an antibiotic on the human gut microbiota, as revealed
568 by deep 16S rRNA sequencing. PLoS Biol **6:**e280.
569 13. **Eckburg, P. B., E. M. Bik, C. N. Bernstein, E. Purdom, L. Dethlefsen,**
570 **M. Sargent, S. R. Gill, K. E. Nelson, and D. A. Relman.** 2005. Diversity
571 of the Human Intestinal Microbial Flora. Science **308:**1635-1638.
572 14. **Edgar, R. C.** 2004. MUSCLE: multiple sequence alignment with high
573 accuracy and high throughput. Nucleic Acids Res **32:**1792-7.

574 15. **Frank, D. N., and N. R. Pace.** 2008. Gastrointestinal microbiology enters
575 the metagenomics era. Curr Opin Gastroenterol **24:**4-10.
576 16. **Freter, R.** 1962. In vivo and in vitro antagonism of intestinal bacteria
577 against Shigellaflexneri. II. The inhibitory mechanism. J Infect Dis **110:**38-
578 46.
579 17. **Gotelli, N. J., and R. K. Colwell.** 2001. Quantifying biodiversity:
580 procedures and pitfalls in the measurement and comparison of species
581 richness. Ecology Letters **4:**379-391.
582 18. **Hentges, D. J., and R. Freter.** 1962. In vivo and in vitro antagonism of
583 intestinal bacteria against *Shigella flexneri*. I. Correlation between various
584 tests. J Infect Dis **110:**30-7.
585 19. **Holdeman, L. V., I. J. Good, and W. E. Moore.** 1976. Human fecal flora:
586 variation in bacterial composition within individuals and a possible effect of
587 emotional stress. Appl Environ Microbiol **31:**359-75.
588 20. **Hooper, L. V., J. Xu, P. G. Falk, T. Midtvedt, and J. I. Gordon.** 1999. A
589 molecular sensor that allows a gut commensal to control its nutrient
590 foundation in a competitive ecosystem. Proc Natl Acad Sci U S A
591 **96:**9833-8.
592 21. **Huber, J. A., D. B. Mark Welch, H. G. Morrison, S. M. Huse, P. R. Neal,**
593 **D. A. Butterfield, and M. L. Sogin.** 2007. Microbial population structures
594 in the deep marine biosphere. Science **318:**97-100.
595 22. **Huse, S. M., L. Dethlefsen, J. A. Huber, D. M. Welch, D. A. Relman,**
596 **and M. L. Sogin.** 2008. Exploring microbial diversity and taxonomy using
597 SSU rRNA hypervariable tag sequencing. PLoS Genet **4:**e1000255.
598 23. **Huse, S. M., J. A. Huber, H. G. Morrison, M. L. Sogin, and D. M.**
599 **Welch.** 2007. Accuracy and quality of massively parallel DNA
600 pyrosequencing. Genome Biol **8:**R143.
601 24. **Ivanov, II, L. Frutos Rde, N. Manel, K. Yoshinaga, D. B. Rifkin, R. B.**
602 **Sartor, B. B. Finlay, and D. R. Littman.** 2008. Specific microbiota direct
603 the differentiation of IL-17-producing T-helper cells in the mucosa of the
604 small intestine. Cell Host Microbe **4:**337-49.
605 25. **Jernberg, C., S. Lofmark, C. Edlund, and J. K. Jansson.** 2007. Long-
606 term ecological impacts of antibiotic administration on the human intestinal
607 microbiota. Isme J **1:**56-66.
608 26. **Kang, S. S., S. M. Bloom, L. A. Norian, M. J. Geske, R. A. Flavell, T. S.**
609 **Stappenbeck, and P. M. Allen.** 2008. An antibiotic-responsive mouse
610 model of fulminant ulcerative colitis. PLoS Med **5:**e41.
611 27. **Kelly, D., and S. Conway.** 2005. Bacterial modulation of mucosal innate
612 immunity. Mol Immunol **42:**895-901.
613 28. **Ley, R. E., M. Hamady, C. Lozupone, P. J. Turnbaugh, R. R. Ramey, J.**
614 **S. Bircher, M. L. Schlegel, T. A. Tucker, M. D. Schrenzel, R. Knight,**
615 **and J. I. Gordon.** 2008. Evolution of mammals and their gut microbes.
616 Science **320:**1647-51.
617 29. **Ley, R. E., D. A. Peterson, and J. I. Gordon.** 2006. Ecological and
618 evolutionary forces shaping microbial diversity in the human intestine. Cell
619 **124:**837-48.

620 30. **Ley, R. E., P. J. Turnbaugh, S. Klein, and J. I. Gordon.** 2006. Microbial
621 ecology: human gut microbes associated with obesity. Nature **444:**1022-3.
622 31. **Little, A. E., C. J. Robinson, S. B. Peterson, K. F. Raffa, and J.**
623 **Handelsman.** 2008. Rules of engagement: interspecies interactions that
624 regulate microbial communities. Annu Rev Microbiol **62:**375-401.
625 32. **Lofmark, S., C. Jernberg, J. K. Jansson, and C. Edlund.** 2006.
626 Clindamycin-induced enrichment and long-term persistence of resistant
627 *Bacteroides* spp. and resistance genes. J Antimicrob Chemother **58:**1160-
628 7.
629 33. **Madsen, K. L., J. S. Doyle, M. M. Tavernini, L. D. Jewell, R. P. Rennie,**
630 **and R. N. Fedorak.** 2000. Antibiotic therapy attenuates colitis in
631 interleukin 10 gene-deficient mice. Gastroenterology **118:**1094-105.
632 34. **Magurran, A. E.** 2004. Measuring Biological Diversity, vol. Blackwell
633 Science Ltd., Oxford, UK.
634 35. **Maroo, S., and J. T. Lamont.** 2006. Recurrent *Clostridium difficile*.
635 Gastroenterology **130:**1311-6.
636 36. **Maukonen, J., R. Satokari, J. Matto, H. Soderlund, T. Mattila-**
637 **Sandholm, and M. Saarela.** 2006. Prevalence and temporal stability of
638 selected clostridial groups in irritable bowel syndrome in relation to
639 predominant faecal bacteria. J Med Microbiol **55:**625-33.
640 37. **Membrez, M., F. Blancher, M. Jaquet, R. Bibiloni, P. D. Cani, R. G.**
641 **Burcelin, I. Corthesy, K. Mace, and C. J. Chou.** 2008. Gut microbiota
642 modulation with norfloxacin and ampicillin enhances glucose tolerance in
643 mice. FASEB J **22:**2416-26.
644 38. **Mylonakis, E., E. T. Ryan, and S. B. Calderwood.** 2001. *Clostridium*
645 *difficile*--Associated diarrhea: A review. Arch Intern Med **161:**525-33.
646 39. **Nadkarni, M. A., F. E. Martin, N. A. Jacques, and N. Hunter.** 2002.
647 Determination of bacterial load by real-time PCR using a broad-range
648 (universal) probe and primers set. Microbiology **148:**257-66.
649 40. **Nitsche, A., M. Becker, I. Junghahn, J. Aumann, O. Landt, I. Fichtner,**
650 **B. Wittig, and W. Siegert.** 2001. Quantification of human cells in
651 NOD/SCID mice by duplex real-time polymerase-chain reaction.
652 Haematologica **86:**693-9.
653 41. **Pace, N. R.** 1997. A molecular view of microbial diversity and the
654 biosphere. Science **276:**734-40.
655 42. **Peterson, D. A., D. N. Frank, N. R. Pace, and J. I. Gordon.** 2008.
656 Metagenomic approaches for defining the pathogenesis of inflammatory
657 bowel diseases. Cell Host Microbe **3:**417-27.
658 43. **Rakoff-Nahoum, S., J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R.**
659 **Medzhitov.** 2004. Recognition of commensal microflora by toll-like
660 receptors is required for intestinal homeostasis. Cell **118:**229-41.
661 44. **Samuel, B. S., and J. I. Gordon.** 2006. A humanized gnotobiotic mouse
662 model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A
663 **103:**10011-6.
664 45. **Sanders, M. E.** 2008. Probiotics: definition, sources, selection, and uses.
665 Clin Infect Dis **46 Suppl 2:**S58-61; discussion S144-51.

666 46. **Sansonetti, P. J., and J. P. Di Santo.** 2007. Debugging how bacteria
667 manipulate the immune response. Immunity **26:**149-61.
668 47. **Sartor, R. B.** 2008. Microbial influences in inflammatory bowel diseases.
669 Gastroenterology **134:**577-94.
670 48. **Savage, D. C.** 1977. Microbial ecology of the gastrointestinal tract. Annu
671 Rev Microbiol **31:**107-33.
672 49. **Scanlan, P. D., F. Shanahan, C. O'Mahony, and J. R. Marchesi.** 2006.
673 Culture-independent analyses of temporal variation of the dominant fecal
674 microbiota and targeted bacterial subgroups in Crohn's disease. J Clin
675 Microbiol **44:**3980-8.
676 50. **Schloss, P. D., and J. Handelsman.** 2005. Introducing DOTUR, a
677 computer program for defining operational taxonomic units and estimating
678 species richness. Appl Environ Microbiol **71:**1501-6.
679 51. **Schmittgen, T. D., and K. J. Livak.** 2008. Analyzing real-time PCR data
680 by the comparative C(T) method. Nat Protoc **3:**1101-8.
681 52. **Sekirov, I., N. M. Tam, M. Jogova, M. L. Robertson, Y. Li, C. Lupp, and**
682 **B. B. Finlay.** 2008. Antibiotic-induced perturbations of the intestinal
683 microbiota alter host susceptibility to enteric infection. Infect Immun
684 **76:**4726-36.
685 53. **Shreiner, A., G. B. Huffnagle, and M. C. Noverr.** 2008. The "Microflora
686 Hypothesis" of allergic disease. Adv Exp Med Biol **635:**113-34.
687 54. **Sogin, M. L., H. G. Morrison, J. A. Huber, D. Mark Welch, S. M. Huse,**
688 **P. R. Neal, J. M. Arrieta, and G. J. Herndl.** 2006. Microbial diversity in
689 the deep sea and the underexplored "rare biosphere". Proc Natl Acad Sci
690 U S A **103:**12115-20.
691 55. **Sogin, M. L., H. G. Morrison, J. A. Huber, D. M. Welch, S. M. Huse, P.**
692 **R. Neal, J. M. Arrieta, and G. J. Herndl.** 2006. Microbial diversity in the
693 deep sea and the underexplored "rare biosphere". Proc Natl Acad Sci U S
694 A **103:**12115-20.
695 56. **Turnbaugh, P. J., R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis,**
696 **and J. I. Gordon.** 2006. An obesity-associated gut microbiome with
697 increased capacity for energy harvest. Nature **444:**1027-31.
698 57. **Tvede, M., and J. Rask-Madsen.** 1989. Bacteriotherapy for chronic
699 relapsing *Clostridium difficile* diarrhoea in six patients. Lancet **1:**1156-60.
700 58. **Vanhoutte, T., V. De Preter, E. De Brandt, K. Verbeke, J. Swings, and**
701 **G. Huys.** 2006. Molecular monitoring of the fecal microbiota of healthy
702 human subjects during administration of lactulose and *Saccharomyces*
703 *boulardii*. Appl Environ Microbiol **72:**5990-7.
704 59. **Vollaard, E. J., and H. A. Clasener.** 1994. Colonization resistance.
705 Antimicrob Agents Chemother **38:**409-14.
706 60. **Walker, W. A.** 2008. Mechanisms of action of probiotics. Clin Infect Dis **46**
707 **Suppl 2:**S87-91; discussion S144-51.
708 61. **Wilson, K. H.** 1993. The microecology of *Clostridium difficile*. Clin Infect
709 Dis **16 Suppl 4:**S214-8.

710 62. **Wilson, K. H., and R. B. Blitchington.** 1996. Human colonic biota
711 studied by ribosomal DNA sequence analysis. Appl Environ Microbiol
712 **62:**2273-8.
713 63. **Zoetendal, E. G., A. D. Akkermans, and W. M. De Vos.** 1998.
714 Temperature gradient gel electrophoresis analysis of 16S rRNA from
715 human fecal samples reveals stable and host-specific communities of
716 active bacteria. Appl Environ Microbiol **64:**3854-9.
717
718

719 **Acknowledgments**

720 We thank Nabeetha Nagalingam, Judith Opp and Jason Pratt for assistance with
721 animal experimentation and Katia Andreishcheva and Christina Holmes for
722 assistance with 454 sequencing. Thanks to Courtney Robinson for critical
723 reading of the manuscript. The main projects were funded in whole with federal
724 funds from the NIAID, NIH, Department of Health and Human Services, under
725 contract number N01-AI-30058. Additional funding was supplied via subcontracts
726 from the Woods Hole Center for Oceans and Human Health from the National
727 Institutes of Health and National Science Foundation (NIH/NIEHS 1 P50
728 ES012742-01 and NSF/OCE 0430724-J. Stegeman PI to H.G.M. and M.L.S. and
729 R01 DK070875 to V.B.Y.) and a grants from the W.M. Keck Foundation and the
730 G. Unger Vetlesen Foundation (to M.L.S.). D.A.A. was supported by the National
731 Institutes of Health under a Ruth L. Kirschstein National Research Service Award
732 (T32 HL07749). The manuscript's contents are solely the responsibility of the
733 authors and do not necessarily represent the official views of the NIH.

734 # Figure legends

735

736 Figure 1. **Schemata for antibiotic administration.** A. Fifteen C57BL/6 IL-10$^{-/-}$
737 mice received the combination of amoxicillin, metronidazole and bismuth in their
738 chow for 10 days while 10 animals remained on control chow. Mice were either
739 euthanized immediately after antibiotic administration or after a 2-week period of
740 recovery on non-medicated chow. Control animals remained on non-medicated
741 chow for the entire experiment. B. Five animals remained on sterile water while
742 15 mice were treated with 0.5 mg/ml of cefoperazone in sterile drinking water for
743 10 days. The antibiotic-treated animals were subsequently divided into three
744 groups. One group of 3 animals was immediately sacrificed. One group of 6
745 animals (divided into two cages) was returned to sterile water without antibiotics
746 for a 6-week recovery period. A final group of 6 animals (also divided into two
747 cages) was returned to water without antibiotics, and a non-treated control
748 mouse was added to the cage for the 6-week recovery period. The cecae of all
749 animals were harvested for microbial community analysis.

750

751 Figure 2. **Comparison of the microbial community composition in the cecae**
752 **of antibiotic treated mice.** Over one million V6 sequence tags were retrieved
753 and classified from cecal DNA purified from untreated mice (Control), animals
754 that received amoxicillin, metronidazole and bismuth (AMB) in chow for 10 days
755 (Antibiotic Treated) or AMB-treated mice that were allowed to recover on plain
756 chow for two weeks (Recovery). The sequence tags were classified to the level

757 of bacterial division (phylum). The pie charts show the distribution of the pooled
758 tags for each experimental group with the mean ± S.D. distribution of tags
759 recovered from each individual animal is indicated.
760
761 Figure 3. **Genus level diversity of the gut communities in the cecae of**
762 **control animals.** Approximately 16,000 V6 SSU hypervariable region tags were
763 retrieved from the cecal mucosa-associated microbiota from each of three wild-
764 type C57BL/6 mice. Pie charts show the distribution for the most prevalent
765 taxonomically assigned tags while the percentages for the 12 most common
766 assignments is indicated below. Bray-Curtis similarities were calculated for each
767 pairwise comparison. The nonparametric Chao1 diversity estimator was
768 calculated for each community based on 97% sequence similarity.
769
770 Figure 4. **Comparison of microbial communities in cefoperazone-treated**
771 **animals.** Over 300,000 V6 sequence tags were retrieved from the cecae of
772 cefoperazone treated mice that recovered from drug treatment in the presence or
773 absence of an untreated "donor" animal. The tags were assigned a taxonomy at
774 the level of genus and the pair-wise Bray-Curtis distance calculated for all
775 possible comparisons. The Bray-Curtis values are presented in a heatmap
776 fashion as a color-coded distance matrix with the most similar (Bray-Curtis
777 similarity of 1.0) represented by blue and the most dissimilar (Bray-Curtis
778 similarity of 0.0) represented in red. The housing of the animals is indicated and
779 the animals that served as "donor" in each cage are marked with a star.

780

781 Figure 5 **Genus level diversity of the gut communities from cefoperazone-**

782 **treated animals.** The taxonomic assignments of V6 tags from untreated animals

783 (control), animals that recovered without an untreated animal (isolated recovery)

784 and animals that recovered in the presence of an untreated animal (donor

785 recovery) are shown. The pie charts show the most abundant genus level

786 assigned tags for the pooled animals in each experimental group. The average (±

787 S.D.) distribution of tags recovered from each individual animal is indicated

788 below. ND = not detected.

789

790 Figure 6 **Rarefaction analysis of microbial communities from cefoperazone**

791 **treated animals.** The number of assigned phylotypes as a function of the

792 number of tags retrieved. The V6 tags from untreated animals (control), animals

793 that recovered without an untreated animal (isolated recovery) and animals that

794 recovered in the presence of an untreated animal (donor recovery) were used to

795 construct rarefaction curves with an OTU definition of >97% sequence similarity.

796
797 **Table 1** Bray-Curtis similarities comparing communities from AMB-treated mice
798

	Control	Recover	Treated
Control (n=9)	0.765 ± 0.014[a1]		
Recover (n=11)	0.756 ± 0.008[a]	0.749 ± 0.011[a]	
Treated (n=2)	0.212 ± 0.019[b]	0.205 ± 0.018[b]	0.845 ± 0.083[a]

799
800 [1] average ± S.D.
801 [a,b] values not connected by the same letter are significantly different. Groups
802 were compared by ANOVA with significance set at $p < 0.05$ by Tukey Kramer.
803


A.
C57BL/6 IL-10-/- mice
(25 mice total)
control - no drug
(10 mice)
amoxicillin/
metronidazole/bismuth
10 days
(15 mice)
no recovery
(5 mice)
recovery off drug
2 weeks
(10 mice)
harvest cecum for
microbial community
analysis
B.
C57BL/6 mice
(20 mice total)
control - no drug
(5 mice)
cefoperazone
10 days
(15 mice)
recovery off drug
with donor 6 weeks
(8 mice - 2 cages)
recovery off drug
no donor 6 weeks
(6 mice - 2 cages)
no recovery
(3 mice)
transfer
controls
(2 mice)
harvest cecum for
microbial community
analysis
(3 mice)


Control
Antibiotic Treated
Recovery
Phylum level tag assignment
Bacteroidetes
Firmicutes
Proteobacteria
Other Bacterial phyla
1.1 ± 1.1
1.1 ± 0.5
23.3 ± 13.2
74.4 ± 12.3
0.14 ± 0.11
16.8 ± 4.5
7.5 ± 5.2
75.5 ± 9.9
6.0 ± 4.9
1.6 ± 0.6
22.1 ± 12.0
70.1 ± 11.8
number of animals
number of tags
9
435,893
2
102,801
10
467,253



Genus level tag assignment	Percentage of total community		
Firmicutes Lachnospiraceae NA	43.8	47.9	43.3
Bacteroidetes Porphyromonadaceae NA	11.4	15.2	14.9
Proteobacteria Pseudomonadaceae Pseudomonas	10.8	6.3	8.9
Firmicutes NA	9.5	8.7	6.6
Firmicutes Ruminococcaceae NA	7.6	5.5	7.0
Firmicutes Ruminococcaceae Paillibacter	4.5	4.8	4.9
Bacteria NA	2.8	3.3	3.7
Firmicutes ErysipelotichaceaeTuricibacter	1.9	0.9	0.5
Firmicutes Clostridiaceae NA	0.8	0.8	0.4
Firmicutes NA Bryantella	0.8	0.8	0.8
Firmictues Rumunococcaceae Ruminococcus	0.8	0.3	1.1
Firmicutes Eubacteriaceae Anaerovorax	0.6	0.5	0.5


Donor Recovery
Isolated Recovery
Control
cage 2
cage 1
cage 2
cage 1
Control
Isolated Recovery
cage 1
cage 2
Donor Recovery
cage 1
cage 2
Similar
Dissimilar
Donor animal



	control	isolated recovery	donor recovery
number of animals	3	6	8
average intragroup similarity	0.91 ± 0.02	0.84 ± 0.06	0.85 ± 0.06

Genus level tag assignment	**Average percentage (±S.D.)**		
Bacteroidetes Lachnospiraceae NA	47 ± 2.4	73 ± 3.8	46 ± 7.8
Bacteroidetes Porphyromonadaceae NA	15 ± 2.3	0.1 ± .24	18 ± 4.1
Proteobacteria Pseudomonadaceae Pseudomonas	8.9 ± 2.8	5.5 ± 3.1	6.1 ± 3.3
Firmicutes Ruminococcaceae NA	8.1 ± 0.8	1.4 ± 1.3	11 ± 2.5
Firmicutes NA NA	7.9 ± 1.8	6.2 ± 5.9	4.9 ± 0.9
Firmicutes Ruminococcaceae Papillibacter	5.0 ± 0.3	4.1 ± 3.8	6.0 ± 1.0
Bacteria NA NA	3.5 ± .52	0 (ND)	1.2 ± 0.62
Firmicutes Erysipleotrichaceae Turicibacter	1.2 ± .72	0.5 ± 0.6	1.3 ± 0.3
Firmicutes Ruminococcaceae Ruminococcus	0.91 ± 0.27	0 (ND)	0.8 ± 0.34
Firmicutes NA Bryantella	0.83 ± 0.045	0.8 ± 1.2	0.6 ± 0.17
Firmicutes Eubacteriaceae Anaerovorax	0.54 ± 0.51	0 (ND)	0.39 ± 0.09
Firmicutes Burkholderiaceae Ralstonia	0.4 ± 0.14	0.23 ± 0.2	0.33 ± 0.24
Firmicutes Clostridiaceae Clostridium	0.3 ± 0.18	8.6 ± 5.4	0.45 ± 0.28
Firmicutes Erysiplotrichaceae Allobaculum	0.07 ± 0.02	0.023 ± 0.056	3.1 ± 2.0
Firmicutes Clostridia NA	0.53 ± 0.30	0 (ND)	0.35 ± 0.10



control
isolated recovery
donor recovery
OTUs (0.97)
1400
1200
1000
800
600
400
200
0.5x10⁴
1x10⁴
1.5x10⁴
2x10⁴
2.5x10⁴
V6 tag sequences